Product image of Monmibi (Copper Tetramibi Tetrafluoroborate) supplied by GNH India

Monmibi

Active Ingredient:
Copper Tetramibi Tetrafluoroborate
Origin:
EU

Monmibi (Copper Tetramibi Tetrafluoroborate)

Copper Tetramibi Tetrafluoroborate, the active ingredient in Monmibi, is a copper‑based compound presented as an intravenous formulation for clinical use. It is investigated for potential antimicrobial activity and is intended for administration under professional medical supervision in accordance with EU manufacturing standards.

GNH India supplies Monmibi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Manufacturer / TM Owner

Monrol Europe Srl

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Monmibi contains copper tetramibi tetrafluoroborate, a copper‑based agent studied for its antimicrobial properties.

  • No approved therapeutic indication: currently limited to clinical research settings.
  • Investigational use in resistant bacterial infections: evaluated for activity against multidrug‑resistant strains.
  • Potential use in antifungal research: examined for synergistic effects with existing agents.
  • Exploratory application in oncology: studied for copper‑mediated cytotoxicity.

How It Works

  • Copper tetramibi tetrafluoroborate releases copper ions that interact with microbial enzymes and cellular membranes, generating reactive oxygen species and disrupting essential metabolic pathways. This multi‑target activity underlies its investigated antimicrobial and cytotoxic effects, while also influencing metal‑dependent biological processes.

Side Effects

Common Side Effects

  • Infusion site pain: mild discomfort at the injection site.
  • Fever: transient low‑grade temperature elevation.
  • Nausea: occasional mild upset stomach.
  • Headache: brief episodes during or after infusion.
  • Transient hypotension: short‑lived blood pressure drop.
  • Flushing: temporary reddening of skin.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate treatment.
  • Renal impairment: reduced kidney function observed in some patients.
  • Hepatic enzyme elevation: increased liver enzymes indicating possible liver stress.
  • Hemolysis: destruction of red blood cells.
  • Thrombocytopenia: lowered platelet count.
  • Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient suitability and monitor for adverse events.

  • Monitor renal function: assess serum creatinine before and during treatment.
  • Assess hepatic enzymes: obtain baseline liver function tests and repeat as needed.
  • Observe for hypersensitivity: discontinue immediately if severe allergic signs appear.
  • Use caution in copper metabolism disorders: patients with Wilson's disease may accumulate excess copper.
  • Avoid concurrent copper supplements: risk of copper overload.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Copper tetramibi tetrafluoroborate may interact with several drug classes; careful assessment is required.

Major Interactions (Avoid)

  • Concurrent use with other copper supplements: risk of copper overload.
  • Co‑administration with nephrotoxic agents: increased potential for renal injury.
  • Combination with strong oxidizing agents: may enhance oxidative damage.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (e.g., warfarin): possible alteration of INR.
  • Beta‑lactam antibiotics: additive nephrotoxicity risk.
  • Loop diuretics: may affect copper excretion and electrolyte balance.

Frequently Asked Questions

Monmibi is an intravenous formulation containing copper tetramibi tetrafluoroborate. It is currently employed in clinical research settings to explore its antimicrobial and cytotoxic potential. It has no approved therapeutic indication and is administered under specialist supervision.

The compound delivers copper ions that can interact with microbial enzymes and cellular membranes, generating reactive oxygen species and disrupting metabolic pathways. This multi‑target activity underlies its investigated antimicrobial and anticancer effects.

Dosing is determined by the treating physician based on the specific study protocol, patient characteristics, and clinical judgment. No standardized dose is publicly established for routine therapeutic use.

Safety data are limited. Because copper complexes can cross the placenta and are excreted in milk, Monmibi should be avoided during pregnancy and lactation unless the potential benefit justifies the potential risk and it is prescribed by a qualified specialist.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with other copper‑containing compounds, Monmibi is formulated for intravenous delivery and is designed to provide a controlled release of copper ions. Its investigational profile focuses on broader antimicrobial activity, whereas some alternatives are limited to specific infections or are used as dietary supplements.

Store at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use and discard any solution that appears discolored or particulate.

Monmibi is given by intravenous infusion under aseptic conditions. The infusion rate and duration are set by the prescribing clinician, typically using a calibrated infusion pump and monitoring the patient for any adverse reactions during and after administration.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, renal impairment, hepatic toxicity, hemolysis, and cardiac arrhythmias. Immediate medical attention is required if any of these events occur.

Monmibi should be avoided in patients with known copper metabolism disorders (e.g., Wilson’s disease), severe renal or hepatic dysfunction, a history of severe allergic reactions to copper‑containing products, and in pregnant or breastfeeding women unless a specialist determines that benefits outweigh risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Copper Tetramibi Tetrafluoroborate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT